Full Report

Format

Full Report
Summary (Text)
Summary (XML)

Send to:

Choose Destination

File
Clipboard
Collections

phenprocoumon response - Dosage

MedGen UID:: 1002871
•Concept ID:: CN322728
•: Sign or Symptom

Professional guidelines

PubMed

Pharmacogenetics aspects of oral anticoagulants therapy.

Militaru FC, Vesa SC, Pop TR, Buzoianu AD
J Med Life 2015 Apr-Jun;8(2):171-5. PMID: 25866574 Free PMC Article

Genotype-Guided Dosing of Coumarin Anticoagulants: A Meta-analysis of Randomized Controlled Trials.

Tang T, Liu J, Zuo K, Cheng J, Chen L, Lu C, Han S, Xu J, Jia Z, Ye M, Pei E, Zhang X, Li M
J Cardiovasc Pharmacol Ther 2015 Jul;20(4):387-94. Epub 2015 Jan 8 doi: 10.1177/1074248414565666. PMID: 25575537

Obesity is associated with a slower response to initial phenprocoumon therapy whereas CYP2C9 genotypes are not.

Meyer zu Schwabedissen C, Mevissen V, Schmitz F, Woodruff S, Langebartels G, Rau T, Zerres K, Hoffmann R, Ortlepp JR
Eur J Clin Pharmacol 2006 Sep;62(9):713-20. Epub 2006 Jul 18 doi: 10.1007/s00228-006-0158-3. PMID: 16847664

See all (5)

Recent clinical studies

Etiology

Pharmacogenomics of Oral Antithrombotic Drugs.

Storelli F, Daali Y, Desmeules J, Reny JL, Fontana P
Curr Pharm Des 2016;22(13):1933-49. doi: 10.2174/1381612822666151208122845. PMID: 26642774

Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.

Verhoef TI, Redekop WK, Daly AK, van Schie RM, de Boer A, Maitland-van der Zee AH
Br J Clin Pharmacol 2014 Apr;77(4):626-41. doi: 10.1111/bcp.12220. PMID: 23919835 Free PMC Article

Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes.

Teichert M, Eijgelsheim M, Uitterlinden AG, Buhre PN, Hofman A, De Smet PA, Visser LE, Stricker BH
Pharmacogenet Genomics 2011 Jan;21(1):26-34. doi: 10.1097/FPC.0b013e32834154fb. PMID: 21063236

Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.

Beinema M, Brouwers JR, Schalekamp T, Wilffert B
Thromb Haemost 2008 Dec;100(6):1052-7. PMID: 19132230

VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement.

Schalekamp T, Brassé BP, Roijers JF, van Meegen E, van der Meer FJ, van Wijk EM, Egberts AC, de Boer A
Clin Pharmacol Ther 2007 Feb;81(2):185-93. Epub 2006 Dec 27 doi: 10.1038/sj.clpt.6100036. PMID: 17192772

See all (33)

Diagnosis

Usefulness of phenprocoumon for the treatment of obstructing thrombus in bioprostheses in the aortic valve position.

Jander N, Kienzle RP, Kayser G, Neumann FJ, Gohlke-Baerwolf C, Minners J
Am J Cardiol 2012 Jan 15;109(2):257-62. Epub 2011 Oct 14 doi: 10.1016/j.amjcard.2011.08.038. PMID: 22000772

Alteration of pharmacokinetics of lepirudin caused by anti-lepirudin antibodies occurring after long-term subcutaneous treatment in a patient with recurrent VTE due to Behcets disease.

Linnemann B, Greinacher A, Lindhoff-Last E
Vasa 2010 Feb;39(1):103-7. doi: 10.1024/0301-1526/a000012. PMID: 20186683

Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice.

Becquemont L
Eur J Clin Pharmacol 2008 Oct;64(10):953-60. Epub 2008 Aug 30 doi: 10.1007/s00228-008-0542-2. PMID: 18758764

Determination of bleeding risk using genetic markers in patients taking phenprocoumon.

Hummers-Pradier E, Hess S, Adham IM, Papke T, Pieske B, Kochen MM
Eur J Clin Pharmacol 2003 Jul;59(3):213-9. Epub 2003 May 1 doi: 10.1007/s00228-003-0580-8. PMID: 12728288

In vitro bleeding test with PFA-100-aspects of controlling individual acetylsalicylic acid induced platelet inhibition in patients with cardiovascular disease.

Peters AJ, Borries M, Gradaus F, Jax TW, Schoebel FC, Strauer BE
J Thromb Thrombolysis 2001 Dec;12(3):263-72. doi: 10.1023/a:1015231226086. PMID: 11981109

See all (5)

Therapy

Pharmacogenomics of Oral Antithrombotic Drugs.

Storelli F, Daali Y, Desmeules J, Reny JL, Fontana P
Curr Pharm Des 2016;22(13):1933-49. doi: 10.2174/1381612822666151208122845. PMID: 26642774

Effect of Body Weight on Dose of Vitamin K Antagonists.

Self TH, Wallace JL, Sakaan S, Sands CW
South Med J 2015 Oct;108(10):637-43. doi: 10.14423/SMJ.0000000000000356. PMID: 26437201

Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.

Verhoef TI, Redekop WK, Daly AK, van Schie RM, de Boer A, Maitland-van der Zee AH
Br J Clin Pharmacol 2014 Apr;77(4):626-41. doi: 10.1111/bcp.12220. PMID: 23919835 Free PMC Article

Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters.

Geisen C, Luxembourg B, Watzka M, Toennes SW, Sittinger K, Marinova M, von Ahsen N, Lindhoff-Last E, Seifried E, Oldenburg J
Eur J Clin Pharmacol 2011 Apr;67(4):371-381. Epub 2010 Nov 26 doi: 10.1007/s00228-010-0950-y. PMID: 21110013 Free PMC Article

Pharmacogenetics of oral anticoagulants: a basis for dose individualization.

Stehle S, Kirchheiner J, Lazar A, Fuhr U
Clin Pharmacokinet 2008;47(9):565-94. doi: 10.2165/00003088-200847090-00002. PMID: 18698879

See all (50)

Prognosis

Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.

Verhoef TI, Redekop WK, Daly AK, van Schie RM, de Boer A, Maitland-van der Zee AH
Br J Clin Pharmacol 2014 Apr;77(4):626-41. doi: 10.1111/bcp.12220. PMID: 23919835 Free PMC Article

Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters.

Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice.

Becquemont L
Eur J Clin Pharmacol 2008 Oct;64(10):953-60. Epub 2008 Aug 30 doi: 10.1007/s00228-008-0542-2. PMID: 18758764

VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement.

Clinically important drug interactions with anticoagulants. An update.

Harder S, Thürmann P
Clin Pharmacokinet 1996 Jun;30(6):416-44. doi: 10.2165/00003088-199630060-00002. PMID: 8792056

See all (24)

Clinical prediction guides

Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.

Verhoef TI, Redekop WK, Daly AK, van Schie RM, de Boer A, Maitland-van der Zee AH
Br J Clin Pharmacol 2014 Apr;77(4):626-41. doi: 10.1111/bcp.12220. PMID: 23919835 Free PMC Article

Randomised trial of a clinical dosing algorithm to start anticoagulation with phenprocoumon.

Caduff Good A, Nobel D, Krähenbühl S, Geisen C, Henz S
Swiss Med Wkly 2013;143:w13709. Epub 2013 Jan 8 doi: 10.4414/smw.2013.13709. PMID: 23299853

Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters.

Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice.

Becquemont L
Eur J Clin Pharmacol 2008 Oct;64(10):953-60. Epub 2008 Aug 30 doi: 10.1007/s00228-008-0542-2. PMID: 18758764

Clinically important drug interactions with anticoagulants. An update.

Harder S, Thürmann P
Clin Pharmacokinet 1996 Jun;30(6):416-44. doi: 10.2165/00003088-199630060-00002. PMID: 8792056

See all (22)

Recent systematic reviews

Use of vitamin K antagonists and risk of prostate cancer: Meta-analysis and nationwide case-control study.

Kristensen KB, Jensen PH, Skriver C, Friis S, Pottegård A
Int J Cancer 2019 Apr 1;144(7):1522-1529. Epub 2018 Nov 13 doi: 10.1002/ijc.31886. PMID: 30246248

See all (1)

MedGen

National Center for Biotechnology Information

Send to:

phenprocoumon response - Dosage

Professional guidelines

PubMed

Recent clinical studies

Etiology

Diagnosis

Therapy

Prognosis

Clinical prediction guides

Recent systematic reviews

Supplemental Content

Table of contents

Clinical resources

Practice guidelines

Consumer resources

Reviews

Related information

Recent activity